The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival of patients with metastatic renal cell carcinoma with or without brain metastases.
 
Michael Hurwitz
Employment - Arvinas (I); Faeth Therapeutics (I); Gamida Cell (I); Pfizer (I)
Stock and Other Ownership Interests - Arvinas (I)
Consulting or Advisory Role - Affini-T Therapeutics; Bristol-Myers Squibb/Celgene; crispr therapeutics; Exelixis; Janssen; Nektar; pliant; Regeneron; TScan Therapeutics
Research Funding - Achilles Therapeutics; Achilles Therapeutics; Apexigen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Endocyte; Endocyte; Genentech; Genmab; Innocrin Pharma; Iovance Biotherapeutics; Lilly; Lyell Immunopharma; Lyell Immunopharma; Merck; Nektar; Novartis; Novartis; Pfizer; Progenics; Sanofi/Aventis; Seagen; Synthekine; Torque; Unum Therapeutics; Xilio Therapeutics
 
Bryden Considine
No Relationships to Disclose
 
Nitzan Hasson
No Relationships to Disclose
 
Noam Savion Gaiger
No Relationships to Disclose
 
Melanie Nelson
No Relationships to Disclose
 
Veronica Chiang
Consulting or Advisory Role - Monteris Medical; MRI Interventions
Expert Testimony - Monteris Medical
 
Harriet Kluger
Consulting or Advisory Role - Bristol-Myers Squibb; ChemoCentryx; Clinigen Group; Eisai; GI Reviewers; Gigagen; Invox; Iovance Biotherapeutics; Merck; Pliant; Seranova Bio; Signatera; Werewolf Pharma
Speakers' Bureau - Merck
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
David Braun
Stock and Other Ownership Interests - CurIOS Therapeutics; Elephas Bio; Fortress Biotech (subsidiary)
Consulting or Advisory Role - 2nd.MD; Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Compugen; CurIOS Therapeutics; Dedham Group; Defined Health; DLA Piper; Eisai; Elephas Bio; Exelixis; Insight Strategy; Link Cell Therapies; Merck; Neomorph; Octane Co.; Pfizer; Pfizer; Schlesinger Associates; Scholar Rock; Scholar Rock; Scholar Rock; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
David Schoenfeld
No Relationships to Disclose
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Asher Biotherapeutics; EvolveImmune Therapeutics; GlaxoSmithKline; Intensity Therapeutics; Johnson & Johnson/Janssen; Nextcure; Normunity; Oncohost; Repertoire Immune Medicines; Rootpath
Consulting or Advisory Role - Adaptimmune; Alligator Bioscience; AnaptysBio; Bioinvent; Biond Biologics; BioNTech; Bristol-Myers Squibb; Cullinan Oncology; Dragonfly Therapeutics; GII Innovation; IDEAYA Biosciences; Immatics; Innate Pharma; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Kadmon; Lyvgen Biopharma; Merck; Molecular Partners; Numab; Pfizer; Pierre Fabre; PIOtx; Pliant; Regeneron; Sanofi; Simcha Therapeutics; Sumitomo Pharma Oncology; Turnstone Bio; Verastem; Xilio Therapeutics
 
Michael Leapman
(OPTIONAL) Uncompensated Relationships - Veracyte